Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT04187872 Terminated - Clinical trials for Hepatocellular Carcinoma

LITT and Pembrolizumab in Recurrent Brain Metastasis

TORCH
Start date: January 10, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).

NCT ID: NCT04183062 Active, not recruiting - Clinical trials for Osteosarcoma Metastatic

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

Start date: October 4, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study of an investigational drug, BIO-11006, for the treatment of lung metastases in pediatric patients with advanced osteosarcoma or Ewing's sarcoma. This study will enroll up to 10 patients aged between 5 and 21 at Nicklaus Children's Hospital in Miami, FL. Patients will receive BIO-11006 in addition to chemotherapy consisting of gemcitabine and docetaxel. This study will test the hypothesis that BIO-11006 will enhance the effect of the gemcitabine and docetaxel chemotherapy to treat lung metastases in osteosarcoma and Ewing's sarcoma.

NCT ID: NCT04180501 Recruiting - Brain Metastases Clinical Trials

SRS Sequential Sindilimab in Brain Metastasis of NSLSC

Start date: November 2019
Phase: Phase 2
Study type: Interventional

A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab

NCT ID: NCT04178759 Recruiting - Liver Metastases Clinical Trials

Impact of Chemotherapy and Regenerative Markers of Liver Regeneration After Liver Resection for Liver Metastases

VULSK-Hep
Start date: September 1, 2019
Phase: N/A
Study type: Interventional

Liver is special organ, which can regenerate. On that ability there are many treatment modalities, where liver resection is performed, especially in cancer patients with liver metastases. Liver regeneration provides an opportunity for these patients to undergo multiple treatment regimes and liver resections to achieve curability. There are many factors that impair liver regeneration. One of these factors is chemotherapy. Literature data on impact of chemotherapy to liver regeneration is ambiguous. Therefore we aim to research impact of chemotherapy to liver regeneration.

NCT ID: NCT04178343 Completed - Clinical trials for Leptomeningeal Metastasis

Tomotherapy for Leptomeningeal Metastases

Start date: September 1, 2014
Phase: N/A
Study type: Interventional

This clinical trial was designed to investigate the efficiency and toxicity of tomotherapy for leptomeningeal metastases.

NCT ID: NCT04178330 Completed - Brain Metastases Clinical Trials

Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases

Start date: September 1, 2014
Phase: N/A
Study type: Interventional

This clinical trial was designed to investigate the efficiency and toxicity of tomotherapy as primary radiotherapy for multiple brain metastases.

NCT ID: NCT04177056 Recruiting - Breast Cancer Clinical Trials

Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief

SOLAR-P
Start date: December 4, 2020
Phase: N/A
Study type: Interventional

Radiation therapy has been shown to be very effective at relieving pain caused by bone metastases. However, certain types of cancers such as prostate, breast, kidney, and melanoma can have resistance to radiation, making treatment less successful. Stereotactic body radiotherapy (SBRT) is a newer form of focused treatment that gives higher doses of radiation without damage to surrounding organs. It often is used to help control and cure disease, but less commonly as a way to palliate and treat symptoms. This study is looking at using SBRT for the purposes of improving pain caused by bone metastases in prostate cancer, breast cancer, kidney cancer, and melanoma patients. It is theorized that the higher levels of radiation may be able to combat the resistance some tumour cells have to radiotherapy and provide improved pain response to treatment. The investigators are looking to show that SBRT has a role in helping this group of patients deal with painful bone lesions from their cancer without increasing side effects and toxicity from the radiation treatment.

NCT ID: NCT04173676 Recruiting - Clinical trials for Detection Rate of SLN ; Accuracy Rate of Lymph Node Metastasis

Sentinel Lymph Node Navigation Surgery Using Near-infrared Imaging in Early Esophageal Cancer

Start date: December 2, 2019
Phase: Phase 1
Study type: Interventional

The esophageal squamous cell carcinoma (ESCC) has high prevalence and mortality in China, which become a severe challenge for public health. Esophagectomy is the preferred choice for the patients who are diagnosed with ESCC in early stage .Although three-field lymphadenectomy has improved patient survival and reduced tumor recurrence, Surgery-related complications increased dramatically. It has become a research hotspot to find an effective detection method to identify the lymph node metastasis of ESCC and avoid ineffective expanded lymphadenectomy .The molecular imaging technology has been developed for intra-operative visualization and precise resection of the tumors. Indocyanine Green for Injection (ICG) has been used as a contrast agent in the near-infrared imaging system for the surgical navigation technology, which has a relatively positive effect in the clinical application of gastric cancer and liver cancer.There are few reports on the application of ICG near-infrared imaging tracer lymph nodes in the surgery of ESCC. This study intends to identify the detection rate of sentinel lymph node (SLN) and determine the accuracy of regional lymph node metastasis in ESCC by ICG near-infrared imaging technique, which provides clinical evidence for subsequent precise resection of the lymph nodes. This will be one-arm prospective trial. The ESCC patients will be recruited with strict criteria. 84 patients will be enrolled between18 and 75 years old, without gender limit. The submucosal injection of ICG will be performed preoperatively by gastroscopy on the superior and inferior edge of the esophageal tumor. NIR fluorescence imaging will be performed intraoperatively to observe the lymph nodes. The luminescent lymph node is defined as SLN. According to the standard procedure, 3 field lymphadenectomy will be performed, and all the resected lymph nodes will be subjected to pathological analysis including correlation study of fluorescence signal and tumor tissue in pathology slice. This clinical trial is anticipated to evaluate the detection rate of SLN in ESCC with ICG near-infrared fluorescence imaging and determine the accuracy of regional lymph node metastasis.

NCT ID: NCT04172857 Completed - Glaucoma Secondary Clinical Trials

Treatment of Malignant Glaucoma by Anterior Vitrectomy From Two Different Approaches

Start date: May 1, 2015
Phase:
Study type: Observational

To compare the surgical outcomes of treating phacoemulsification with intraocular lens implantation combined with goniosynechialysis (Phaco-IOL-GSL) associated malignant glaucoma (MG), using different incision sites in anterior vitrectomy combined with hyaloidotomy, zonulectomy, and iridectomy (VHZI).

NCT ID: NCT04172467 Completed - Clinical trials for Secondary Immunodeficiencies (SID)

Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients

QS-SID
Start date: January 28, 2020
Phase:
Study type: Observational

Retrospective, representative registry for quality assurance on diagnosis and therapy of secondary immunodeficiencies (SID) in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM)